Based on the recent earnings conference call transcript of the company, it is apparent that the company has shown strong revenue growth in the first quarter. The product-related revenue of $294 million represents a 43% growth over the same period last year, and the first quarter Jakafi royalties of $29 million represent a 32% growth over the same period last year. The company expects its gross-to-net adjustment for the full year 2017 to be approximately 13%, which is a positive indication for future profitability.

Additionally, the company has entered into new collaborations, expanding its product pipeline, and has made significant advancements in its clinical development programs, as evidenced by the announcement to enter into multiple additional Phase 3 studies with epacadostat. This shows a strong commitment to innovation and future growth.

From a financial perspective, the company has significantly de-levered its balance sheet in a cost-effective manner and expects to have over $600 million in cash and marketable securities by the end of the year. The company also expects to have a net loss for the full year of approximately $150 million to $170 million, but when excluding upfront and milestone expenses and note conversion expenses, it forecasts net income for the full year to be approximately $90 million to $120 million.

In conclusion, the company's strong revenue growth, commitment to innovation and expansion, and solid financial position make it a favorable investment opportunity. Therefore, an 'overweight' investment stance is recommended based on the insights and financial metrics derived from the recent earnings conference call transcript.